Talk:RA Capital Management

This article is rated Start-class on Wikipedia's content assessment scale.
It is of interest to the following WikiProjects:

United States: Massachusetts / Boston Low‑importance

	United States portal This article is within the scope of WikiProject United States, a collaborative effort to improve the coverage of topics relating to the United States of America on Wikipedia. If you would like to participate, please visit the project page, where you can join the ongoing discussions. Template Usage Articles Requested! Become a Member Project Talk Alerts United StatesWikipedia:WikiProject United StatesTemplate:WikiProject United StatesUnited States
Low	This article has been rated as Low-importance on the project's importance scale.
	Massachusetts portal This article is supported by WikiProject Massachusetts (assessed as Low-importance).
	Massachusetts portal This article is supported by WikiProject Massachusetts - Boston (assessed as Low-importance).

Companies Low‑importance

This article is within the scope of WikiProject Companies, a collaborative effort to improve the coverage of companies on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.CompaniesWikipedia:WikiProject CompaniesTemplate:WikiProject Companiescompany

Low This article has been rated as Low-importance on the project's importance scale.

WikiProject Companies To-do:

Here are some tasks awaiting attention:

Article requests : Wikipedia:Requested articles/Business and economics/Companies
Assess : Category:Unassessed company articles
Copyedit : Category:Company articles needing attention
Infobox : Category:Company articles needing infoboxes
Maintain : Portal:Companies
Stubs : Help expand stub articles located at Category:Company stubs
Other :
- Tag company articles with the {{portal|Companies}} template
- Tag company talk pages with the {{WikiProject Companies}} project banner
- Answer requests for comments

Finance & Investment Low‑importance

	This article is within the scope of WikiProject Finance & Investment, a collaborative effort to improve the coverage of articles related to Finance and Investment on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Finance & InvestmentWikipedia:WikiProject Finance & InvestmentTemplate:WikiProject Finance & InvestmentFinance & Investment
Low	This article has been rated as Low-importance on the project's importance scale.

Private Equity

This article is within the scope of the WikiProject Private Equity, a collaborative effort to improve the depth of quality and coverage of the private equity and venture capital industry and related topics in Wikipedia. If you would like to participate, please visit the project page, where you can join the project and see a list of open tasks.

This project seeks to collaborate with the following WikiProjects:

Private EquityWikipedia:WikiProject Private EquityTemplate:WikiProject Private EquityPrivate Equity

Page updates

The user below has a request that an edit be made to RA Capital Management. That user has an actual or apparent conflict of interest.
The requested edits backlog is moderate. Please be patient. There are currently 149 requests waiting for review.

Please read the instructions for the parameters used by this template for accepting and declining them, and review the request below and make the edit if it is well sourced, neutral, and follows other Wikipedia guidelines and policies.

This article doesn’t seem to have been significantly updated since 2019. I’m an employee of RA Capital and I’d like to suggest some updates to the page. I was advised by User:Brucemyboy1212 of WhiteHatWiki and am following COI procedure per Wikipedia:FAQ/Article subjects. Would a neutral editor mind having a look, as suggested at the Wikipedia conflict of interest page?

1. What I think should be changed:

Please change the title of the Background section to “History” and replace the first paragraph:

Change from:

“Background”

RA Capital was founded in January 2002 by Richard Aldrich and Peter Kolchinsky. Aldrich was the chief business officer Vertex Pharmaceuticals who left to set up his own company. He invited Kolchinsky, a PhD student at Harvard University to join him due his technical expertise. The firm's name comes from the initials of Richard Aldrich.^[1]^[2]^[3]

Change to:

“History”

The company that would become RA Capital was started in 2001 by Richard Aldrich, a co-founder of Vertex Pharmaceuticals.^[2] In 2002, Aldrich hired Peter Kolchinskly, who was earning his doctorate in virology from Harvard, to invest $4 million of seed money in biotech.^[3] RA Capital, named after Aldrich, was officially formed in 2004.^[2]

Why it should be changed:

The section describes the company’s development from founding to present, making History - which seems to be the standard section header in articles about companies Tesla, Inc., Chicago Options Associates) - the more accurate title. I suggested a rewrite of the first paragraph to correctly order the sources so that they support each sentence. I suggested cutting the Institutional Investor source because it was only used to support Kolchinsky’s education, which is already supported by Barron's article.

2. What I think should be changed:

In the current Background section, please add a new ninth paragraph:

In 2019, the firm started an incubator called Carnot to test the viability of early-stage biotechnology companies.^[4] As of 2020, the firm had begun operating an incubator program called RAVentures to help develop new and early-stage companies working in biotechnology.^[5]

Why it should be changed: As it is now, the article is missing information about the company beyond one mention in 2019.

3. What I think should be changed:

In the current Background section, please add a new tenth paragraph (following paragraph proposed in item B):

In 2020, the firm’s second venture fund, Nexus Fund II, raised $461 million.^[6] The firm’s third venture fund, Nexus Fund III, raised $880 million in 2021.^[7]

Why it should be changed:

The article currently has information about the company’s first venture fund, but is missing info about the second and third.

Thank you for taking the time to review these suggestions. Landis215 (talk) 17:46, 26 February 2025 (UTC)[reply]

^ "Investing in the Health Care Revolution". Institutional Investor. January 4, 2016. Retrieved May 19, 2023.
^ ^a ^b ^c Edelson, Steve (February 22, 2016). "BioCentury" (PDF). RA Capital.
^ ^a ^b Shari, Michael. "Stocks Picks From a Top Biotech Hedge Fund". online.barrons.com. Retrieved May 19, 2023.
^ Sheridan, Kate (23 September 2019). "RA Capital launches Carnot, an incubator for early-stage biotechs". Stat. Retrieved 10 December 2024.
^ Keown, Alex (22 October 2020). "RA Capital Closes $461 Million Investment Fund Aimed at Life Sciences Companies". BioSpace. Retrieved 10 February 2025.
^ Taylor, Nick Paul (2 October 2022). "Fresh from early successes, RA Capital bags $461M for new fund". Fierce Biotech. Retrieved 1 December 2024.
^ Smith, Johnathan (20 December 2023). "The Top Five Venture Capital Heavyweights in Life Sciences". Inside Precision Medicine. Retrieved 7 December 2024.

[:0-1] "Investing in the Health Care Revolution". Institutional Investor. January 4, 2016. Retrieved May 19, 2023.

[:1-2] Edelson, Steve (February 22, 2016). "BioCentury" (PDF). RA Capital.

[:2-3] Shari, Michael. "Stocks Picks From a Top Biotech Hedge Fund". online.barrons.com. Retrieved May 19, 2023.

[4] Sheridan, Kate (23 September 2019). "RA Capital launches Carnot, an incubator for early-stage biotechs". Stat. Retrieved 10 December 2024.

[5] Keown, Alex (22 October 2020). "RA Capital Closes $461 Million Investment Fund Aimed at Life Sciences Companies". BioSpace. Retrieved 10 February 2025.

[6] Taylor, Nick Paul (2 October 2022). "Fresh from early successes, RA Capital bags $461M for new fund". Fierce Biotech. Retrieved 1 December 2024.

[IPM23-7] Smith, Johnathan (20 December 2023). "The Top Five Venture Capital Heavyweights in Life Sciences". Inside Precision Medicine. Retrieved 7 December 2024.

[1]

[2]

[3]

[4]

[5]

[6]

[7]